MAPT and tauopathy: To determine a causal role between senescent cells and tauopathy, we administered intermittent (once every two weeks) senolytic therapy (D+Q) to tau transgenic mice between the ages of 20–23 months old with already present tau pathology, neurodegeneration, inflammation and brain atrophy (35).